Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 4Terminated 2Unknown 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 98Lymphoid 48Other hematologic neoplasm 37Thoracic 7Genitourinary 6Gastrointestinal 5CNS 4Breast 4Tumor-Agnostic 3Myeloid 3Gynecologic 2Other solid neoplasm 1Head & Neck 1Endocrine 1Classical hematology 1

Conditions

Pediatric Solid Tumor, Unspecified, Protocol Specific 1

Interventions

Injections 54pembrolizumab 39Carboplatin 20Bevacizumab 19Cyclophosphamide 18toripalimab 15tislelizumab 14fludarabine 14Nivolumab 14Cisplatin 14Specimen Handling 13Paclitaxel 13Interviews as Topic 13Pemetrexed 12Standard of Care 11Practice Guidelines as Topic 11Oxaliplatin 11Cetuximab 11Fluorouracil 10atezolizumab 9Educational Status 9Docetaxel 9Capecitabine 9Leucovorin 8Methods 7Etoposide 7Early Intervention, Educational 7spartalizumab 6olaparib 6Ipilimumab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Dexamethasone × Other solid neoplasm × Clear all
NCT06208917 2024-01-17

Ondansetron (ODF) Versus Ondansetron Intravenously for the Prevention of Chemotherapy-induced Nausea and Vomiting Compare in Children

Sun Yat-sen University

Phase 3 Recruiting
376 enrolled
Other solid neoplasm

Pediatric Solid Tumor, Unspecified, Protocol Specific

Data powered by HemOnc (CC BY 4.0) Colophon âš¡